PDF(Pubmed)
Abstract：
UNASSIGNED: To evaluate the effects of behavioral intervention for polycystic ovary syndrome (PCOS).
UNASSIGNED: Electronic databases were searched, including Pubmed, Medline, EMBASE, and the Cochrane Central Register of Controlled Trials from inception to 1 April 2023. Inclusion criteria for this study required a diagnosis of PCOS. Interventions of interest included behavioral intervention and routine treatment compared with routine treatment. The studies included in the analysis were designed as randomized controlled trials (RCTs). We conducted meta-analyses following the recommended guidelines. The data was analyzed using either the random effects model or fixed effects model. The results of the studies were expressed as either mean differences (MD) or standardized mean differences (SMD) along with their corresponding 95% confidence intervals (CIs).
UNASSIGNED: Eight RCTs were identified, including data from 744 patients (415 in the intervention group and 329 in the control group). The results indicate an improvement in the effectiveness of behavioral interventions for weight loss (MD: -1.07; 95% CI: -2.1 to 0.03; I2 = 0%; P=0.04), body mass index (BMI) (MD: -1.12; 95% CI: -1.92 to -0.33; I2 = 73%; P=0.006), waist circumference (MD: -3.97; 95% CI: -5.64 to -2.29; I2 = 0%; P<0.00001), quality of life about weight (MD: 0.58; 95% CI: 0.15 to 1.02; I2 = 0%; P=0.008), depression (SMD: -1.12; 95% CI: -2.35 to -0.07; I2 = 92%; P=0.04), and triglycerides (MD: -0.16; 95% CI: -0.27 to -0.05; I2 = 27%; P=0.004). However, there were no significant differences in menstrual cycles, hirsutism, emotions, and infertility. The study also found that behavioral interventions had no significant effect on systolic and diastolic blood pressure, high-density lipoprotein, low-density lipoprotein, homeostasis model assessment of insulin resistance, testosterone, total cholesterol, fasting glucose, fasting insulin, hemoglobin A1C, and sex hormone binding globulin.
UNASSIGNED: Behavioral intervention supplementation contributes to weight loss, reduction in BMI and waist circumference, and improvement in depression among patients with PCOS. However, no significant improvement was observed in the biochemical index and quality of life. The long-term effects of behavioral intervention for PCOS remain unclear due to limitations in the quality of the studies involved and the short duration of treatment.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023442875.
UNASSIGNED: Electronic databases were searched, including Pubmed, Medline, EMBASE, and the Cochrane Central Register of Controlled Trials from inception to 1 April 2023. Inclusion criteria for this study required a diagnosis of PCOS. Interventions of interest included behavioral intervention and routine treatment compared with routine treatment. The studies included in the analysis were designed as randomized controlled trials (RCTs). We conducted meta-analyses following the recommended guidelines. The data was analyzed using either the random effects model or fixed effects model. The results of the studies were expressed as either mean differences (MD) or standardized mean differences (SMD) along with their corresponding 95% confidence intervals (CIs).
UNASSIGNED: Eight RCTs were identified, including data from 744 patients (415 in the intervention group and 329 in the control group). The results indicate an improvement in the effectiveness of behavioral interventions for weight loss (MD: -1.07; 95% CI: -2.1 to 0.03; I2 = 0%; P=0.04), body mass index (BMI) (MD: -1.12; 95% CI: -1.92 to -0.33; I2 = 73%; P=0.006), waist circumference (MD: -3.97; 95% CI: -5.64 to -2.29; I2 = 0%; P<0.00001), quality of life about weight (MD: 0.58; 95% CI: 0.15 to 1.02; I2 = 0%; P=0.008), depression (SMD: -1.12; 95% CI: -2.35 to -0.07; I2 = 92%; P=0.04), and triglycerides (MD: -0.16; 95% CI: -0.27 to -0.05; I2 = 27%; P=0.004). However, there were no significant differences in menstrual cycles, hirsutism, emotions, and infertility. The study also found that behavioral interventions had no significant effect on systolic and diastolic blood pressure, high-density lipoprotein, low-density lipoprotein, homeostasis model assessment of insulin resistance, testosterone, total cholesterol, fasting glucose, fasting insulin, hemoglobin A1C, and sex hormone binding globulin.
UNASSIGNED: Behavioral intervention supplementation contributes to weight loss, reduction in BMI and waist circumference, and improvement in depression among patients with PCOS. However, no significant improvement was observed in the biochemical index and quality of life. The long-term effects of behavioral intervention for PCOS remain unclear due to limitations in the quality of the studies involved and the short duration of treatment.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023442875.
摘要：
■评估行为干预对多囊卵巢综合征（PCOS）的影响。
■搜索了电子数据库，包括Pubmed,Medline,EMBASE,和Cochrane中央受控试验登记册从开始到2023年4月1日。这项研究的纳入标准需要诊断为PCOS。与常规治疗相比，感兴趣的干预措施包括行为干预和常规治疗。分析中包括的研究被设计为随机对照试验(RCTs)。我们按照推荐的指南进行了荟萃分析。使用随机效应模型或固定效应模型分析数据。研究结果以平均差（MD）或标准化平均差（SMD）及其相应的95％置信区间（CI）表示。
■确定了八个RCT，包括744例患者的数据(干预组415例,对照组329例).结果表明，行为干预措施对减肥的有效性有所改善（MD：-1.07；95％CI：-2.1至0.03；I2=0％；P=0.04），身体质量指数（BMI）（MD：-1.12；95％CI：-1.92至-0.33；I2=73％；P=0.006），腰围（MD：-3.97；95％CI：-5.64至-2.29；I2=0％；P<0.00001），关于体重的生活质量（MD：0.58;95％CI：0.15至1.02;I2=0％;P=0.008），抑郁（SMD：-1.12；95%CI：-2.35至-0.07；I2=92%；P=0.04），和甘油三酯(MD:-0.16;95%CI:-0.27至-0.05;I2=27%;P=0.004)。然而,月经周期没有显着差异，多毛症,情感,和不孕症。研究还发现,行为干预对收缩压和舒张压没有显著影响,高密度脂蛋白，低密度脂蛋白，胰岛素抵抗的稳态模型评估，睾丸激素，总胆固醇,空腹血糖,空腹胰岛素，血红蛋白A1C，和性激素结合球蛋白.
■行为干预补充剂有助于减肥，降低BMI和腰围，和改善PCOS患者的抑郁。然而,生化指标和生活质量无显著改善.行为干预对PCOS的长期影响尚不清楚，原因是研究质量有限，治疗时间短。
■https://www.crd.约克。AC.英国/PROSPERO,标识符CRD42023442875。
■搜索了电子数据库，包括Pubmed,Medline,EMBASE,和Cochrane中央受控试验登记册从开始到2023年4月1日。这项研究的纳入标准需要诊断为PCOS。与常规治疗相比，感兴趣的干预措施包括行为干预和常规治疗。分析中包括的研究被设计为随机对照试验(RCTs)。我们按照推荐的指南进行了荟萃分析。使用随机效应模型或固定效应模型分析数据。研究结果以平均差（MD）或标准化平均差（SMD）及其相应的95％置信区间（CI）表示。
■确定了八个RCT，包括744例患者的数据(干预组415例,对照组329例).结果表明，行为干预措施对减肥的有效性有所改善（MD：-1.07；95％CI：-2.1至0.03；I2=0％；P=0.04），身体质量指数（BMI）（MD：-1.12；95％CI：-1.92至-0.33；I2=73％；P=0.006），腰围（MD：-3.97；95％CI：-5.64至-2.29；I2=0％；P<0.00001），关于体重的生活质量（MD：0.58;95％CI：0.15至1.02;I2=0％;P=0.008），抑郁（SMD：-1.12；95%CI：-2.35至-0.07；I2=92%；P=0.04），和甘油三酯(MD:-0.16;95%CI:-0.27至-0.05;I2=27%;P=0.004)。然而,月经周期没有显着差异，多毛症,情感,和不孕症。研究还发现,行为干预对收缩压和舒张压没有显著影响,高密度脂蛋白，低密度脂蛋白，胰岛素抵抗的稳态模型评估，睾丸激素，总胆固醇,空腹血糖,空腹胰岛素，血红蛋白A1C，和性激素结合球蛋白.
■行为干预补充剂有助于减肥，降低BMI和腰围，和改善PCOS患者的抑郁。然而,生化指标和生活质量无显著改善.行为干预对PCOS的长期影响尚不清楚，原因是研究质量有限，治疗时间短。
■https://www.crd.约克。AC.英国/PROSPERO,标识符CRD42023442875。
